Nakyung Jeon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nakyung Jeon has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Sun-Young Jung
College of Pharmacy, Chung-Ang University, Seoul, Korea
3 shared publications - Christine Elizabeth Staatz
School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia
2 shared publications Haesuk Park
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida
2 shared publications- Haesuk Park
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, USA
2 shared publications In-Hwan Baek
College of Pharmacy, Kyungsung University, Busan, Republic of Korea
2 shared publications- In-Hwan Baek
College of Pharmacy, Kyungsung University, Busan, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Korean Society for Pharmacoepidemiology and Risk Management in Journal of Pharmacoepidemiology and Risk Management
- Vol. 18 (2) , 172-182
Age-Stratified Safety Signal Analysis of Methylphenidate and Atomoxetine Using Adverse Event Reporting System Database: Children vs. Adults
Yumi Kim and Nakyung Jeon. Pharmacoepidemiology and Risk Management 2026;18:172-82. https://doi.org/10.56142/perm.26.0013
- 30 September 2026
- Published by Korean Society for Pharmacoepidemiology and Risk Management in Journal of Pharmacoepidemiology and Risk Management
- Vol. 18 (2) , 172-182
Open AccessAge-Stratified Safety Signal Analysis of Methylphenidate and Atomoxetine Using Adverse Event Reporting System Database: Children vs. Adults
Yumi Kim and Nakyung Jeon. Pharmacoepidemiology and Risk Management 2026;18:172-82. https://doi.org/10.56142/perm.26.0013
- 20 July 2026
- Published by Springer Nature in Environmental Geochemistry and Health
- Vol. 48 (11) , 473
Irrigation-mediated transfer of geogenic manganese to paddy soils and rice grain in a mine-influenced catchment: a screening-level dietary exposure assessment
Manganese (Mn) contamination in agricultural systems is usually attributed to mining or industrial sources, but hydrologically connected catchments can transfer geogenic Mn to staple crops through irrigation. This study characterized Mn transfer from a mine-influenced, recently disturbed upland to irrigation water, stream sediment, paddy soils, rice tissues, and screening-level dietary exposure in a semi-enclosed catchment in Ilgwang, Busan, South Korea. Surface water and stream sediment were monitored over four agricultural periods in 2021, and paddy soils and rice were sampled from four sequential irrigation zones (P1–P4). Mn was measured by ICP-OES, and solid-phase partitioning was assessed by the modified BCR sequential extraction procedure. Dissolved Mn was strongly enriched along the disturbed-upland drainage pathway (main-flow mean 4.55 ± 1.61 mg/L) relative to tributary inputs (0.16 ± 0.27 mg/L). Stream sediments approached 20,000 mg/kg with more than 97% in non-residual fractions, and paddy soils were enriched up to a field-mean of approximately 1,050 mg/kg (67–83% non-residual). A screening-level, dissolved-Mn flux analysis indicated that the upper paddy zone retained 49.5–56.6% of the seasonal irrigation-derived Mn within the soil–sediment system. Rice grain Mn ranged from 90.64 to 171.47 mg/kg (highest at P3), greatly exceeding typical background levels (1–10 mg/kg). Screening-level hazard quotients exceeded 1 in all zones and remained above 1 for young children even under a conservative 70% bioaccessibility reduction. Because the source was predominantly geogenic and bioaccessibility, cultivar, redox, and pre-disturbance baselines were not directly quantified, these results document an irrigation-mediated exposure pathway rather than a proven causal effect of land disturbance.
- 20 July 2026
- Published by Springer Nature in Environmental Geochemistry and Health
- Vol. 48 (11) , 473
Irrigation-mediated transfer of geogenic manganese to paddy soils and rice grain in a mine-influenced catchment: a screening-level dietary exposure assessment
Manganese (Mn) contamination in agricultural systems is usually attributed to mining or industrial sources, but hydrologically connected catchments can transfer geogenic Mn to staple crops through irrigation. This study characterized Mn transfer from a mine-influenced, recently disturbed upland to irrigation water, stream sediment, paddy soils, rice tissues, and screening-level dietary exposure in a semi-enclosed catchment in Ilgwang, Busan, South Korea. Surface water and stream sediment were monitored over four agricultural periods in 2021, and paddy soils and rice were sampled from four sequential irrigation zones (P1–P4). Mn was measured by ICP-OES, and solid-phase partitioning was assessed by the modified BCR sequential extraction procedure. Dissolved Mn was strongly enriched along the disturbed-upland drainage pathway (main-flow mean 4.55 ± 1.61 mg/L) relative to tributary inputs (0.16 ± 0.27 mg/L). Stream sediments approached 20,000 mg/kg with more than 97% in non-residual fractions, and paddy soils were enriched up to a field-mean of approximately 1,050 mg/kg (67–83% non-residual). A screening-level, dissolved-Mn flux analysis indicated that the upper paddy zone retained 49.5–56.6% of the seasonal irrigation-derived Mn within the soil–sediment system. Rice grain Mn ranged from 90.64 to 171.47 mg/kg (highest at P3), greatly exceeding typical background levels (1–10 mg/kg). Screening-level hazard quotients exceeded 1 in all zones and remained above 1 for young children even under a conservative 70% bioaccessibility reduction. Because the source was predominantly geogenic and bioaccessibility, cultivar, redox, and pre-disturbance baselines were not directly quantified, these results document an irrigation-mediated exposure pathway rather than a proven causal effect of land disturbance.
- Open Access
- 7 May 2026
- Published by The Korean Physiological Society and The Korean Society of Pharmacology in The Korean Journal of Physiology & Pharmacology
- Vol. 30 (6) , 629-639
Similarity-based profiling of pharmacovigilance data for drug safety pattern discovery
Seongjae Park, SeongJin Wi, Heeseon Jo, Yuseong Kwon, Nakyung Jeon, and Haeseung Lee. Korean J Physiol Pharmacol -0001;0:. https://doi.org/10.4196/kjpp.26.080
- 7 May 2026
- Published by The Korean Physiological Society and The Korean Society of Pharmacology in The Korean Journal of Physiology & Pharmacology
- Vol. 30 (6) , 629-639
Open AccessSimilarity-based profiling of pharmacovigilance data for drug safety pattern discovery
Seongjae Park, SeongJin Wi, Heeseon Jo, Yuseong Kwon, Nakyung Jeon, and Haeseung Lee. Korean J Physiol Pharmacol -0001;0:. https://doi.org/10.4196/kjpp.26.080
- 2 April 2026
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 22 (6) , 468-476
Comparative Safety of Long-Acting Versus Short-Acting Erythropoiesis-Stimulating Agents (ESA): Disproportionality Analysis Using the FDA Adverse Event Reporting System
Objectives: Erythropoiesis-stimulating agents (ESAs), classified as long-acting or short-acting, is a primary treatment for anemia in chronic kidney disease and chemotherapy. Given ongoing safety concerns regarding cardiovascular events and potential immunogenic risks associated with PEGylation, this study aims to detect safety signals for long-acting versus short-acting ESAs. Methods: We conducted disproportionality analyses using the FDA Adverse Event Reporting System (FAERS) database. All adverse event (AE) reports related to long-acting and short-acting ESA use from Q1 2018 to Q4 2022 were analyzed, including darbepoetin alfa and methoxy polyethylene glycol-epoetin beta as long-acting ESAs and epoetin alfa and epoetin beta as short-acting ESAs. Data were divided into 2 data sets: ESA as the primary suspect (PS) and ESA as either the PS or secondary suspect (SS). Proportional reporting ratios, reporting odds ratios, and 95% CIs for information components were calculated to identify safety signals. Sensitivity analyses included AE reports with unspecified ESA types to confirm signal consistency. Results: A total of 5702 and 9772 reports for long-acting ESAs, 2487 and 3975 for short-acting ESAs, and 2 and 352 for ESAs with unspecified drug names that could not be classified as either long-acting or short-acting were identified in the PS and PS/SS data sets. In the PS-restricted primary analysis, 10 robust safety signals were identified for long-acting ESAs: back pain, chest pain, drug hypersensitivity, dyspnea, falls, hypotension, pruritus, urinary tract infection, urticaria, and vomiting. Notably, signals such as falls and hypotension were uniquely detected when isolating the PS role and failed to reach the signal threshold in the broader secondary analysis. Conclusions: Our analysis found disproportionately reported AEs for long-acting ESAs, particularly when ESAs were the PS, highlighting the importance of monitoring AEs not listed in the package label, such as falls. Furthermore, despite existing black box warnings regarding cardiovascular risks, our analysis found weak evidence for cardiovascular safety signals strictly attributable to long-acting ESAs. Further studies are needed to confirm the association between these signals and long-acting ESAs.
- 2 April 2026
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 22 (6) , 468-476
Comparative Safety of Long-Acting Versus Short-Acting Erythropoiesis-Stimulating Agents (ESA): Disproportionality Analysis Using the FDA Adverse Event Reporting System
Objectives: Erythropoiesis-stimulating agents (ESAs), classified as long-acting or short-acting, is a primary treatment for anemia in chronic kidney disease and chemotherapy. Given ongoing safety concerns regarding cardiovascular events and potential immunogenic risks associated with PEGylation, this study aims to detect safety signals for long-acting versus short-acting ESAs. Methods: We conducted disproportionality analyses using the FDA Adverse Event Reporting System (FAERS) database. All adverse event (AE) reports related to long-acting and short-acting ESA use from Q1 2018 to Q4 2022 were analyzed, including darbepoetin alfa and methoxy polyethylene glycol-epoetin beta as long-acting ESAs and epoetin alfa and epoetin beta as short-acting ESAs. Data were divided into 2 data sets: ESA as the primary suspect (PS) and ESA as either the PS or secondary suspect (SS). Proportional reporting ratios, reporting odds ratios, and 95% CIs for information components were calculated to identify safety signals. Sensitivity analyses included AE reports with unspecified ESA types to confirm signal consistency. Results: A total of 5702 and 9772 reports for long-acting ESAs, 2487 and 3975 for short-acting ESAs, and 2 and 352 for ESAs with unspecified drug names that could not be classified as either long-acting or short-acting were identified in the PS and PS/SS data sets. In the PS-restricted primary analysis, 10 robust safety signals were identified for long-acting ESAs: back pain, chest pain, drug hypersensitivity, dyspnea, falls, hypotension, pruritus, urinary tract infection, urticaria, and vomiting. Notably, signals such as falls and hypotension were uniquely detected when isolating the PS role and failed to reach the signal threshold in the broader secondary analysis. Conclusions: Our analysis found disproportionately reported AEs for long-acting ESAs, particularly when ESAs were the PS, highlighting the importance of monitoring AEs not listed in the package label, such as falls. Furthermore, despite existing black box warnings regarding cardiovascular risks, our analysis found weak evidence for cardiovascular safety signals strictly attributable to long-acting ESAs. Further studies are needed to confirm the association between these signals and long-acting ESAs.
- Open Access
- 18 July 2025
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 58 (3) , 709-719
Characteristics of Immune Checkpoint Inhibitor (ICI)-Related Hepatotoxicity Based on the Baseline Liver Function
Characteristics of Immune Checkpoint Inhibitor (ICI)-Related Hepatotoxicity Based on the Baseline Liver Function
- 18 July 2025
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 58 (3) , 709-719
Open AccessCharacteristics of Immune Checkpoint Inhibitor (ICI)-Related Hepatotoxicity Based on the Baseline Liver Function
Characteristics of Immune Checkpoint Inhibitor (ICI)-Related Hepatotoxicity Based on the Baseline Liver Function
- Open Access
- 11 July 2025
- Published by Wiley
Comparative safety of long- versus short-acting erythropoiesis-stimulating agents (ESA): Disproportionality analysis using the FDA Adverse Event Reporting System
Objectives Erythropoiesis-stimulating agent (ESA), classified as long- or short-acting, is a primary treatment for anemia in chronic kidney disease and cancer. While studies on the safety profile of ESAs are ongoing until recently, so this study aims to detect safety signals for long- versus short-acting ESAs. Design We conducted disproportionality analyses using the publicly accessible FDA Adverse Reporting System (FAERS) database. Setting and Participants All adverse events (AE) reports related to long- and short-acting ESAs use from January 2018 to December 2022 were analyzed. Methods To identify safety signals, data were divided into two datasets: (1) ESA as the primary suspect (PS) and (2) ESA as either the PS or secondary suspect (SS). For each dataset, proportional reporting ratios, reporting odds ratios, and 95% confidence intervals for information components were calculated to identify safety signals. Main analyses included AE reports of long or short-acting ESAs and were divided into primary and secondary analysis based on ESA roles. Sensitivity analyses included AE reports with unspecified ESA types (long- or short-acting) to confirm consistency of findings. Results A total of 5,702 and 9,772 reports for long-acting ESAs, 2,487 and 3,975 for short-acting ESAs, and 2 and 352 for uncertain ESAs were identified as PS and PS/SS datasets, respectively. Back pain, chest pain, drug hypersensitivity, dyspnea, falls, hypotension, pruritus, urinary tract infection, urticaria, and vomiting were identified as safety signals for long- versus short-acting ESAs in both primary and sensitivity analysis. However, falls and hypotension were not identified as signals in secondary and sensitivity analysis. Conclusions and Implications Our analysis found disproportionately reported AEs for long-acting ESAs, particularly when ESAs were the PS, highlighting the importance of monitoring AEs not listed in package label, such as falls. Further studies are needed to confirm the association between these signals and long-acting ESAs.
- 11 July 2025
- Published by Wiley
Open AccessComparative safety of long- versus short-acting erythropoiesis-stimulating agents (ESA): Disproportionality analysis using the FDA Adverse Event Reporting System
Objectives Erythropoiesis-stimulating agent (ESA), classified as long- or short-acting, is a primary treatment for anemia in chronic kidney disease and cancer. While studies on the safety profile of ESAs are ongoing until recently, so this study aims to detect safety signals for long- versus short-acting ESAs. Design We conducted disproportionality analyses using the publicly accessible FDA Adverse Reporting System (FAERS) database. Setting and Participants All adverse events (AE) reports related to long- and short-acting ESAs use from January 2018 to December 2022 were analyzed. Methods To identify safety signals, data were divided into two datasets: (1) ESA as the primary suspect (PS) and (2) ESA as either the PS or secondary suspect (SS). For each dataset, proportional reporting ratios, reporting odds ratios, and 95% confidence intervals for information components were calculated to identify safety signals. Main analyses included AE reports of long or short-acting ESAs and were divided into primary and secondary analysis based on ESA roles. Sensitivity analyses included AE reports with unspecified ESA types (long- or short-acting) to confirm consistency of findings. Results A total of 5,702 and 9,772 reports for long-acting ESAs, 2,487 and 3,975 for short-acting ESAs, and 2 and 352 for uncertain ESAs were identified as PS and PS/SS datasets, respectively. Back pain, chest pain, drug hypersensitivity, dyspnea, falls, hypotension, pruritus, urinary tract infection, urticaria, and vomiting were identified as safety signals for long- versus short-acting ESAs in both primary and sensitivity analysis. However, falls and hypotension were not identified as signals in secondary and sensitivity analysis. Conclusions and Implications Our analysis found disproportionately reported AEs for long-acting ESAs, particularly when ESAs were the PS, highlighting the importance of monitoring AEs not listed in package label, such as falls. Further studies are needed to confirm the association between these signals and long-acting ESAs.
- Open Access
- 31 March 2025
- Published by Korean Society for Pharmacoepidemiology and Risk Management in Journal of Pharmacoepidemiology and Risk Management
- Vol. 17 (1) , 99-110
Real-World Effectiveness of COVID-19 Vaccnies by Dose in Korea : A Systematic Reivew and Meta-Anlaysis
Geumbi Yun, Hankil Lee, Sewon Joung and Nakyung Jeon. Pharmacoepidemiology and Risk Management 2025;17:99-110. https://doi.org/10.56142/perm.25.0013
- 31 March 2025
- Published by Korean Society for Pharmacoepidemiology and Risk Management in Journal of Pharmacoepidemiology and Risk Management
- Vol. 17 (1) , 99-110
Open AccessReal-World Effectiveness of COVID-19 Vaccnies by Dose in Korea : A Systematic Reivew and Meta-Anlaysis
Geumbi Yun, Hankil Lee, Sewon Joung and Nakyung Jeon. Pharmacoepidemiology and Risk Management 2025;17:99-110. https://doi.org/10.56142/perm.25.0013
- Open Access
- 26 April 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (1) , 72-81
Efficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis
Fibroblast growth factor (FGF)‐21 analogs are potential therapeutic candidates for metabolic dysfunction‐associated steatohepatitis (MASH). This systematic review and meta‐analysis aimed to assess the efficacy and safety of the FGF‐21 analogs, efruxifermin, pegbelfermin, and pegozafermin for MASH treatment. A comprehensive systematic review and meta‐analysis of randomized controlled trials from five major databases was conducted. Primary efficacy outcomes focused on liver histological improvement, while secondary efficacy outcomes encompassed reductions in liver fat content and improvements in biochemical parameters. Safety outcomes examined included treatment‐emergent adverse events (TEAEs), treatment‐related TEAEs, TEAEs leading to discontinuation, and serious TEAEs. Eight eligible studies involving 963 patients were included in this review. Compared with the placebo group, the FGF‐21 analog‐treated group exhibited significantly improved primary efficacy outcomes, specifically ≥1 stage improvement in fibrosis with no worsening of MASH (risk ratio [RR] = 1.83; 95% confidence interval [CI] = 1.27–2.62) and at least two‐point improvement in the non‐alcoholic fatty liver disease activity score with no worsening of fibrosis (RR = 2.85; 95% CI = 2.06–3.95). Despite an increased risk of TEAEs (RR = 1.17; 95% CI = 1.08–1.27) and treatment‐related adverse events (RR = 1.75; 95% CI = 1.40–2.19), FGF‐21 analogs exhibited an acceptable safety profile. FGF‐21 analogs were significantly better in achieving liver histological improvements and beneficial biochemical outcomes compared with placebo, with a tolerable safety pattern. These findings shed light on the efficacy and safety of FGF‐21 analogs and provide valuable evidence for their application as MASH therapeutics.
- 26 April 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (1) , 72-81
Open AccessEfficacy and Safety of Fibroblast Growth Factor‐21 Analogs for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis
Fibroblast growth factor (FGF)‐21 analogs are potential therapeutic candidates for metabolic dysfunction‐associated steatohepatitis (MASH). This systematic review and meta‐analysis aimed to assess the efficacy and safety of the FGF‐21 analogs, efruxifermin, pegbelfermin, and pegozafermin for MASH treatment. A comprehensive systematic review and meta‐analysis of randomized controlled trials from five major databases was conducted. Primary efficacy outcomes focused on liver histological improvement, while secondary efficacy outcomes encompassed reductions in liver fat content and improvements in biochemical parameters. Safety outcomes examined included treatment‐emergent adverse events (TEAEs), treatment‐related TEAEs, TEAEs leading to discontinuation, and serious TEAEs. Eight eligible studies involving 963 patients were included in this review. Compared with the placebo group, the FGF‐21 analog‐treated group exhibited significantly improved primary efficacy outcomes, specifically ≥1 stage improvement in fibrosis with no worsening of MASH (risk ratio [RR] = 1.83; 95% confidence interval [CI] = 1.27–2.62) and at least two‐point improvement in the non‐alcoholic fatty liver disease activity score with no worsening of fibrosis (RR = 2.85; 95% CI = 2.06–3.95). Despite an increased risk of TEAEs (RR = 1.17; 95% CI = 1.08–1.27) and treatment‐related adverse events (RR = 1.75; 95% CI = 1.40–2.19), FGF‐21 analogs exhibited an acceptable safety profile. FGF‐21 analogs were significantly better in achieving liver histological improvements and beneficial biochemical outcomes compared with placebo, with a tolerable safety pattern. These findings shed light on the efficacy and safety of FGF‐21 analogs and provide valuable evidence for their application as MASH therapeutics.
- 17 April 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (1) , 217-224
Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis
Both short‐acting (epoetin alfa or beta) and long‐acting (darbepoetin alfa or PEG‐epoetin) erythropoiesis‐stimulating agents (ESAs) are commonly prescribed for patients with kidney failure undergoing maintenance hemodialysis. We compared the risks of major adverse cardiovascular events (MACE) and of all‐cause mortality associated with receipt of short‐ vs. long‐acting ESAs. This retrospective cohort analysis included Medicare hemodialysis beneficiaries aged ≥ 18 years in the United States Renal Data System from January 2015 to December 2017. We included adults who survived > 90 days after initiating hemodialysis and received either short‐ or long‐acting ESAs. Outcomes were MACE (first occurrence of stroke, acute myocardial infarction, or cardiovascular‐related mortality) and all‐cause mortality. After stabilized inverse probability of treatment weighting, Cox proportional hazards regression models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for each outcome. Of 68,607 patients (mean age: 65 years, 45% females), 33,658 (49%) received long‐acting ESAs and 34,949 (51%) received short‐acting ESAs. There was no difference in the risk of MACE associated with receipt of short‐ vs. long‐acting ESAs (HR: 1.02 (95% CI: 0.98–1.08)). However, long‐acting (vs. short‐acting) ESA receipt was associated with a lower risk of all‐cause mortality (HR: 0.91 (95% CI: 0.87–0.96)). Compared with short‐acting ESAs, long‐acting ESAs were associated with a lower risk of all‐cause mortality, with no difference in the risk of MACE. Future studies with a longer follow‐up are needed to confirm these findings.
- 17 April 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (1) , 217-224
Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis
Both short‐acting (epoetin alfa or beta) and long‐acting (darbepoetin alfa or PEG‐epoetin) erythropoiesis‐stimulating agents (ESAs) are commonly prescribed for patients with kidney failure undergoing maintenance hemodialysis. We compared the risks of major adverse cardiovascular events (MACE) and of all‐cause mortality associated with receipt of short‐ vs. long‐acting ESAs. This retrospective cohort analysis included Medicare hemodialysis beneficiaries aged ≥ 18 years in the United States Renal Data System from January 2015 to December 2017. We included adults who survived > 90 days after initiating hemodialysis and received either short‐ or long‐acting ESAs. Outcomes were MACE (first occurrence of stroke, acute myocardial infarction, or cardiovascular‐related mortality) and all‐cause mortality. After stabilized inverse probability of treatment weighting, Cox proportional hazards regression models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for each outcome. Of 68,607 patients (mean age: 65 years, 45% females), 33,658 (49%) received long‐acting ESAs and 34,949 (51%) received short‐acting ESAs. There was no difference in the risk of MACE associated with receipt of short‐ vs. long‐acting ESAs (HR: 1.02 (95% CI: 0.98–1.08)). However, long‐acting (vs. short‐acting) ESA receipt was associated with a lower risk of all‐cause mortality (HR: 0.91 (95% CI: 0.87–0.96)). Compared with short‐acting ESAs, long‐acting ESAs were associated with a lower risk of all‐cause mortality, with no difference in the risk of MACE. Future studies with a longer follow‐up are needed to confirm these findings.